17 August 2021.
Izon Science has recently executed a Product Development Agreement with BCAL Diagnostics, an Australian-based biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer. To achieve this, BCAL are harnessing EV-lipidomics, i.e., mass spectrometry analysis of lipids derived from extracellular vesicles. Izon Science will work with BCAL in the development of the test and commercialisation of the product. In particular, Izon's equipment and components will be used to enable the separation of extracellular vesicles from other components in plasma samples, and will use automation and ID tracking to accelerate the processing time.
BCAL Diagnostics was listed on Australia’s sharemarket on Wednesday 21st July.
